Evidence map›Paper›PMID 35832445›Full record

ArticleTranslational lung cancer research2022

Clinicopathological characteristics and prognostic significance of HDAC11 protein expression in non-small cell lung cancer: a retrospective study.

Di Lu, Zhiqiang Ma, Di Huang, Jundong Zhang, Jinfeng Li, Peng Zhi, Lizhong Zhang, Yingtong Feng, Xiangwei Ge, Jinzhao Zhai and 8 more

Open access · diamondAbstract read
In one paragraph

Article in Translational lung cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 2 countries.

Di Lu *Medical School of Chinese PLA, Beijing, China.
Zhiqiang Ma *Department of Medical Oncology, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Di Huang *Department of Medical Oncology, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Jundong ZhangMedical School of Chinese PLA, Beijing, China.
Jinfeng LiInstitute of Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Peng ZhiDepartment of Hematology, The Second Medical Center of Chinese PLA General Hospital, Beijing, China.
Lizhong ZhangDepartment of Hematology, The Second Medical Center of Chinese PLA General Hospital, Beijing, China.
Yingtong FengDepartment of Thoracic Surgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.
Xiangwei GeMedical School of Chinese PLA, Beijing, China.
Jinzhao ZhaiMedical School of Chinese PLA, Beijing, China.
Menglong JiangDepartment of Thoracic Surgery, 1st Affiliated Hospital of Anhui Medical University, Hefei, China.
Xin ZhouMedical School of Chinese PLA, Beijing, China.
Charles B SimoneDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Joel W NealDivision of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Shruti Rajesh PatelDivision of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Xiaolong YanDepartment of Thoracic Surgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.
Yi HuDepartment of Medical Oncology, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Jinliang WangDepartment of Medical Oncology, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Chinese PLA General Hospital · CNPLA Academy of Military Science · CNAir Force Medical University · CNAnhui Medical University · CNNew York Proton Center · USShanxi Medical University · CN

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Background: Although the prognosis of non-small cell lung cancer (NSCLC) can be assessed based on pathological type, disease stage and inflammatory indicators, the prognostic scoring model of NSCLC still needs to improve. Methods: The clinicopathological and paracancerous tissues of patients with NSCLC primarily diagnosed in Tangdu Hospital from 2009 to 2013 were collected. Follow-up of patients were made every three months and the last follow-up period was December 2018. The expression of Results: The study assessed 326 patients with NSCLC. Compared with adjacent tissues, Conclusions: The high expression of

Indexed as

HDAC11immunohistochemistrynon-small cell lung cancer (NSCLC)prognosissurvival

Identifiers

PMID35832445
PMCPMC9271448
OpenAlexW4283699773

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.